Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
29/08/2024 13:40
Aug 29 (Reuters) - Orgenesis Inc ORGS.O :
* ORGENESIS ANNOUNCES POSITIVE RESULTS FROM A REAL-WORLD
STUDY OF
ORG-101 CAR-T THERAPY IN PATIENTS WITH CD19+ ACUTE LYMPHOBLASTIC
LEUKEMIA
* ORGENESIS INC: TOP-LINE EFFICACY AND SAFETY DATA FROM
STUDY HAD
A COMPLETE RESPONSE (CR )OF 82% IN ADULT PATIENTS AND 93% IN
PEDIATRIC PATIENTS
* ORGENESIS INC: DATA INDICATE A POTENTIALLY FAVORABLE
SAFETY
PROFILE WITH A LOWER INCIDENCE OF CYTOKINE RELEASE SYNDROME
Source text for Eikon: ID:nGNX4jxJYm
Further company coverage: ORGS.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orgenesis
See all newsBrief: Orgenesis Nasdaq To Delist Co'S Common Stock, Securities Trading Will Be Suspended On Oct 21
Brief: Orgenesis Announces Positive Results From A Real-World Study Of Org-101 Car-T Therapy
Brief: Orgenesis Announces Strategic Partnership With Harley Street Healthcare Group
Brief: Orgenesis Says Entered Purchase Deal With Theracell For Purchase Of 50% Outstanding Ownership Rights & Equity Interests In Theracell Laboratories Ike
Brief: Orgenesis Received Nasdaq Hearings Panel Decision Which Granted Company Until October 14 To Regain Compliance With Bid Price And Equity Rules